Literature DB >> 11918544

Fluoro-deoxyglucose positron emission tomography imaging for the detection of occult disease in multiple myeloma.

Kim Orchard1, Sally Barrington, John Buscombe, Andrew Hilson, Hugh Grant Prentice, Atul Mehta.   

Abstract

Positron emission tomography with 2-deoxy-2-[18]fluoro-D-glucose (FDG-PET) imaging has been extensively used to detect occult metastatic malignant lesions in patients with carcinoma. We describe its use in three patients with multiple myeloma, each representing a particular clinical situation in which this imaging modality offered advantages over plain radiography, computerized tomography or magnetic resonance imaging. FDG-PET provides a whole body image showing sites of occult disease. This is of particular value in patients with non-secretory myeloma, solitary plasmacytoma or for those that relapse with focal disease following autologous or allogeneic stem cell transplantation.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11918544     DOI： 10.1046/j.1365-2141.2002.03407.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


  11 in total

1.  Value of 18F-fluorodeoxyglucose uptake in positron emission tomography/computed tomography in predicting survival in multiple myeloma.

Authors:  Rauf Haznedar; Sahika Z Akı; Ozgür U Akdemir; Zübeyde N Ozkurt; Ozcan Ceneli; Münci Yağcı; Gulsan T Sucak; Mustafa Unlü
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-02-02       Impact factor: 9.236

2.  Multiple myeloma.

Authors:  Conor D Collins
Journal:  Cancer Imaging       Date:  2004-01-14       Impact factor: 3.909

Review 3.  Multiple myeloma.

Authors:  Conor D Collins
Journal:  Cancer Imaging       Date:  2010-02-11       Impact factor: 3.909

Review 4.  Minimal residual disease analysis in myeloma - when, why and where.

Authors:  Uday Yanamandra; Shaji K Kumar
Journal:  Leuk Lymphoma       Date:  2017-10-11

5.  Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology.

Authors:  Kenneth C Anderson; Melissa Alsina; Djordje Atanackovic; J Sybil Biermann; Jason C Chandler; Caitlin Costello; Benjamin Djulbegovic; Henry C Fung; Cristina Gasparetto; Kelly Godby; Craig Hofmeister; Leona Holmberg; Sarah Holstein; Carol Ann Huff; Adetola Kassim; Amrita Y Krishnan; Shaji K Kumar; Michaela Liedtke; Matthew Lunning; Noopur Raje; Seema Singhal; Clayton Smith; George Somlo; Keith Stockerl-Goldstein; Steven P Treon; Donna Weber; Joachim Yahalom; Dorothy A Shead; Rashmi Kumar
Journal:  J Natl Compr Canc Netw       Date:  2015-11       Impact factor: 11.908

6.  Accuracy of whole-body low-dose multidetector CT (WBLDCT) versus skeletal survey in the detection of myelomatous lesions, and correlation of disease distribution with whole-body MRI (WBMRI).

Authors:  T G Gleeson; J Moriarty; C P Shortt; J P Gleeson; P Fitzpatrick; B Byrne; J McHugh; M O'Connell; P O'Gorman; S J Eustace
Journal:  Skeletal Radiol       Date:  2008-11-14       Impact factor: 2.199

7.  Prognostic factors in solitary plasmacytoma of the bone: a multicenter Rare Cancer Network study.

Authors:  David Knobel; Abderrahim Zouhair; Richard W Tsang; Philip Poortmans; Yazid Belkacémi; Michel Bolla; Fazilet Dinçbas Oner; Christine Landmann; Bernard Castelain; Mahmut Ozsahin
Journal:  BMC Cancer       Date:  2006-05-05       Impact factor: 4.430

8.  Problems monitoring response in multiple myeloma.

Authors:  Conor D Collins
Journal:  Cancer Imaging       Date:  2005-11-23       Impact factor: 3.909

9.  Very late antigen-4 (α(4)β(1) Integrin) targeted PET imaging of multiple myeloma.

Authors:  Deepti Soodgupta; Michelle A Hurchla; Majiong Jiang; Alexander Zheleznyak; Katherine N Weilbaecher; Carolyn J Anderson; Michael H Tomasson; Monica Shokeen
Journal:  PLoS One       Date:  2013-02-08       Impact factor: 3.240

10.  M-protein-negative Myeloma Mimicking Lumbar Disc Herniation.

Authors:  Yusuke Hirota; Shingo Suzuki; Yota Katsuyama; Tohru Iseki; Masatomi Ikusaka
Journal:  Intern Med       Date:  2017-07-01       Impact factor: 1.271
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.